http://finance.yahoo.com/news/…procedures-110000075.html
Prochymal® (remestemcel-L) will be evaluated under its Rapid Authorization Procedures. This designation, also known in Switzerland as Fast Track, typically cuts the evaluation period for promising new drugs in half.
The Common Technical Document for Prochymal contains over 90,000 pages of data on the stem cell drug and is similar to the applications filed in Canada and New Zealand.
nun ist osiris auch in der schweiz angekommen, obwohl auch kleiner markt für solch eine stammzellentherapie